Drugmaker Mallinckrodt struck a deal to buy Endo in an effort to build a diversified pharmaceuticals company with a hefty U.S. footprint. The companies said Thursday they reached a definitive ...

The proposed merger comes nearly a year after Endo emerged from bankruptcy protection. Endo Inc. has entered into an agreement to merge with Mallinckrodt in a cash and stock transaction that ...

Mallinckrodt Pharmaceuticals plc and Endo Inc. said Thursday they are combining as part of a stock-and-cash deal with an enterprise value of $6.7 billion that will give both companies a roughly 50 ...

The pairing of Mallinckrodt plc and Endo Inc. is expected to create a pharma heavyweight that will generate $3.6 billion in 2025 revenue after the duo combines their generic pharmaceuticals businesses ...

Mallinckrodt Pharmaceuticals and Endo Inc. plan to merge and create a $6.7 billion company in a move that will cut costs and broaden access to patients and new treatments. The agreement will give ...

Mallinckrodt and Endo, pharmaceutical companies that have each encountered business struggles, announced Thursday a $6.7 billion merger that they contend will result in a combined entity with the ...

Endo shareholders will receive $80 million in cash and own 49.9% of the combined company. The merged firm expects $3.6 billion in 2025 revenue and $1.2 billion in adjusted EBITDA. Feel unsure ...

The combined company will be headquartered in Dublin, Ireland, where Mallinckrodt’s HQ is based, following the close of the merger agreement. Mallinckrodt and Endo said the location of the ...

Mallinckrodt Pharmaceuticals and Endo Inc. are exploring a potential merger that could be valued at about $7 billion, people with knowledge of the matter said. The drugmakers, which both emerged ...